Contrary to our results from transcriptomics in grade 2/3 astrocytomas, in univariable analysis, the difference in survival according to higher or lower HMGB2 expression (mean survival: 15 × 23 months; 95% CI: 13.1–17.9 × 15.4–30.7 months, respectively) was not significant (p = 0.096—Figure 5), corroborating results from public databases [20,33]. Here, HMGB2 is linked to astrocytoma (excluding glioblastoma).